Jennison Associates LLC Agios Pharmaceuticals, Inc. Transaction History

Jennison Associates LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$33.21 - $46.54 $11.9 Million - $16.6 Million	-357,111 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$33.87 - $55.93 $135,276 - $223,384	3,994 Added 1.13%	357,111 $12.5 Million
Q2 2020 Aug 06, 2020	SELL	$34.45 - $53.48 $6.88 Million - $10.7 Million	-199,612 Reduced 36.11%	353,117 $18.9 Million
Q1 2020 May 06, 2020	BUY	$31.52 - $53.81 $137,931 - $235,472	4,376 Added 0.8%	552,729 $19.6 Million
Q4 2019 Feb 07, 2020	BUY	$30.08 - $50.59 $142,849 - $240,251	4,749 Added 0.87%	548,353 $26.2 Million
Q3 2019 Nov 08, 2019	SELL	$32.4 - $49.58 $1.76 Million - $2.69 Million	-54,235 Reduced 9.07%	543,604 $17.6 Million
Q2 2019 Aug 06, 2019	BUY	$46.17 - $68.1 $9.83 Million - $14.5 Million	212,949 Added 55.33%	597,839 $0
Q1 2019 May 10, 2019	BUY	$45.92 - $67.67 $8.79 Million - $12.9 Million	191,359 Added 98.88%	384,890 $26 Million
Q4 2018 Feb 06, 2019	SELL	$42.73 - $76.53 $78,580 - $140,738	-1,839 Reduced 0.94%	193,531 $8.92 Million
Q3 2018 Nov 08, 2018	BUY	$71.67 - $91.95 $102,846 - $131,948	1,435 Added 0.74%	195,370 $15.1 Million
Q2 2018 Aug 02, 2018	BUY	$73.22 - $99.55 $233,059 - $316,867	3,183 Added 1.67%	193,935 $16.3 Million
Q1 2018 Apr 20, 2018	BUY	$59.83 - $86.53 $1.47 Million - $2.12 Million	24,497 Added 14.73%	190,752 $15.6 Million
Q4 2017 Jan 25, 2018	BUY	$52.12 - $72.33 $9,902 - $13,742	190 Added 0.11%	166,255 $9.51 Million
Q3 2017 Nov 03, 2017	BUY	$54.89 - $67.12 $9.12 Million - $11.1 Million	166,065	166,065 $11.1 Million

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.05B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.